Regression of EGFR positive established solid tumors in mice with the conditionally active T cell engager TAK-186

BACKGROUND: Despite clinical success with T cell engagers (TCEs) targeting hematological malignancies, achieving a safe and efficacious dose in patients with solid tumors remains challenging. Due to potency, low levels of target antigen expression on normal tissues may not be tolerated. To overcome...

Descripción completa

Detalles Bibliográficos
Autores principales: Dettling, Danielle E, Kwok, Eilene, Quach, Lucy, Datt, Aakash, Degenhardt, Jeremiah D, Panchal, Anand, Seto, Pui, Krakow, Jessica L, Wall, Russell, Hillier, Brian J, Zhu, Ying, Vinogradova, Maia, DuBridge, Robert B, May, Chad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214390/
https://www.ncbi.nlm.nih.gov/pubmed/35728872
http://dx.doi.org/10.1136/jitc-2021-004336

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214390/
https://www.ncbi.nlm.nih.gov/pubmed/35728872
http://dx.doi.org/10.1136/jitc-2021-004336

Ejemplares similares